Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 23Gemcitabine 9Nivolumab 7Carboplatin 7Trastuzumab 6Early Intervention, Educational 6avelumab 5atezolizumab 5Docetaxel 5Cisplatin 5cemiplimab 4Standard of Care 4Psychiatric Rehabilitation 4Paclitaxel 4Methods 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Fluorouracil 4Fluorodeoxyglucose F18 4Cyclophosphamide 4Counseling 4Albumin-Bound Paclitaxel 4tisotumab vedotin 3pertuzumab 3fludarabine 3Taxes 3Radiotherapy 3Polymerase Chain Reaction 3Gene Expression Profiling 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Brentuximab Vedotin × Gastrointestinal × Clear all
NCT04254107 2025-02-10

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Seagen Inc.

Phase 1 Terminated
133 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡